Android app Apple app link

Health Canada approves GSK's Ojjaara for myelofibrosis in anaemia patients

By Yahoo! Finance   |   1 year ago
Health Canada approves GSK's Ojjaara for myelofibrosis in anaemia patients

Health Canada has approved GlaxoSmithKline's Ojjaara (momelotinib) for treating myelofibrosis in adults with moderate-to-severe anaemia, based on positive results from Phase III trials.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.